Lindus Health, a CRO with a full package of services, and Quotient Sciences, a global clinical development and manufacturing accelerator, have partnered to enable enhanced patient recruitment for Phase I-IIa clinical studies and a seamless pathway from first-in-human (FIH) to proof-of concept (POC) trials. The partnership combines Quotient’s specialized early clinical and drug development capabilities with Lindus’ patient recruitment expertise and later-stage trial delivery. The outcome...